• Explore /
  • Poster
  • / A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).

A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).

Abstract Poster

Authors

Markus Peck-Radosavljevic

Markus Peck-Radosavljevic

Internal Medicine and Gastroenterology (IMuG) with Emergency Medicine (ZAE), Klinikum Klagenfurt am Worthersee, Klagenfurt, Austria

Markus Peck-Radosavljevic , Lipika Goyal , Simone Strasser , Ana Maria Matilla Peña , Rui Marinho , Alessandro Granito , Christoph Roderburg , Mark Marsico , Vanessa C Christou , Ran Xie , Pankhoori Saraf , Tim Meyer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Clinical Trial Registration Number

NCT04763408

DOI

10.1200/JCO.2022.40.4_suppl.TPS485

Abstract #

TPS485

Poster Bd #

R6

Abstract Disclosures

Similar Posters

First Author: Arndt Vogel

First Author: Richard S. Finn

First Author: Carla Pires Amaro

First Author: Timothy J. Brown